Sanofi, J&J and Escherichia coli

J&J, Sanofi stop E.coli vaccine trial due to low effectiveness
Johnson & Johnson and partner Sanofi will stop a late-stage trial of an experimental vaccine to prevent infections caused by the E.coli bacteria due to a lack of sufficient efficacy, the companies said on Thursday.
Sanofi Ends Trial for E. Coli Shot and Takes a $250 Million Hit
Sanofi and Johnson & Johnson ended development of an experimental vaccine after it failed to adequately protect against an invasive form of the digestive pathogen E. coli.
J&J stops Phase III trial of Sanofi’s E. Coli vaccine citing ‘disappointing’ results
The company said it will stop the Phase III trial of ExPEC after interim results found it failed to demonstrate efficacy over placebo.
J&J to Discontinue E.coli Vaccine Candidate Study
Johnson & Johnson said on Thursday it will discontinue a late-stage study of an experimental E.coli vaccine it was developing in partnership with Sanofi. The drugmaker said its decision was based on the recommendation of an independent committee that found the vaccine candidate may not be sufficiently effective compared with a placebo in preventing infections caused by a group of bacteria commonly found in the gut.
Sanofi and J&J discontinue late stage trial of their experimental E.coli vaccine
Sanofi (NASDAQ:SNY) said on Thursday that it is discontinuing the late-stage trial for its vaccine to prevent E. coli bacteria infection as it failed to demonstrate sufficient efficacy. The vaccine for extraintestinal pathogenic E.
Banks on the Hook for Sanofi Buyout Face Agonizing Wait to Sell
Deal-starved banks lined up to make concessions to get a slice of Europe’s biggest buyout debt deal last year. They also put ...
FDA approves Sanofi biosimilar product for treatment of diabetes
The U.S. Food and Drug Administration approved Merilog as biosimilar to Novolog for the improvement of glycemic control in adults and pediatric ...
FierceBiotech2d
Sanofi takes $250M hit after gamble on J&J E. coli vaccine ends in phase 3 failure
A year and a half after Sanofi swooped in on Johnson & Johnson’s dismantled vaccines unit to pick up an E. coli candidate, ...
How Is The Market Feeling About Sanofi?
Sanofi's SNY -1.06% + Free Alerts short percent of float has fallen 8.33% since its last report. The company recently ...
Sanofi price target raised to EUR 110 from EUR 105 at JPMorgan
JPMorgan raised the firm’s price target on Sanofi (SNY) to EUR 110 from EUR 105 and keeps a Neutral rating on the shares.Maximize Your ...
Sanofi gets FDA approval for NovoLog insulin biosimilar
Sanofi (NASDAQ:SNY) has received FDA approval for Merilog, a biosimilar of Novo Nordisk's (NVO) rapid-acting insulin product NovoLog, for the improvement of glycemic control in adults and children ...
FiercePharma8d
Regeneron tangles with Sanofi over commercial transparency in long-running Dupixent collaboration
Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...
policymed.com10d
Sanofi Sues HHS Over 340B Changes
Sanofi-Aventis US LLC filed a lawsuit against the Department of Health and Human Services (HHS) and the Health Resources and ...
WWD on MSN12d
Sanofi Buys Back Shares From L’Oréal
PARIS – L’Oréal has agreed to sell about 29.6 million Sanofi shares to Sanofi for approximately 3 billion euros.
Analysts Conflicted on These Healthcare Names: Sanofi (OtherSNYNF) and Fate Therapeutics (FATE)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sanofi (SNYNF – Research Report) and Fate ...